MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+
| Autor: | F. Barata, H. Queiroga, E. Teixeira, M.T. Almodovar, B. Parente, M. Soares |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: | |
| Zdroj: | Revista Portuguesa de Pneumologia (English Edition), Vol 22, Iss 5, Pp 287-288 (2016) |
| Druh dokumentu: | article |
| ISSN: | 2173-5115 |
| DOI: | 10.1016/j.rppnen.2016.03.009 |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|